CA2500498A1 - Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations - Google Patents
Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations Download PDFInfo
- Publication number
- CA2500498A1 CA2500498A1 CA002500498A CA2500498A CA2500498A1 CA 2500498 A1 CA2500498 A1 CA 2500498A1 CA 002500498 A CA002500498 A CA 002500498A CA 2500498 A CA2500498 A CA 2500498A CA 2500498 A1 CA2500498 A1 CA 2500498A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- hydrogen
- formula
- independently chosen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 title claims abstract 21
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 title claims abstract 21
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 48
- 150000001875 compounds Chemical class 0.000 claims abstract 40
- 239000000203 mixture Substances 0.000 claims abstract 24
- 239000003937 drug carrier Substances 0.000 claims abstract 4
- 230000001404 mediated effect Effects 0.000 claims abstract 4
- 239000002671 adjuvant Substances 0.000 claims abstract 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 30
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 22
- 125000000962 organic group Chemical group 0.000 claims 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 19
- 229910052717 sulfur Inorganic materials 0.000 claims 19
- 239000011593 sulfur Substances 0.000 claims 19
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 claims 16
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 16
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 239000001301 oxygen Substances 0.000 claims 14
- -1 3,4-dihydroxyphenyl Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 6
- 230000037427 ion transport Effects 0.000 claims 6
- 201000003883 Cystic fibrosis Diseases 0.000 claims 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052711 selenium Inorganic materials 0.000 claims 5
- 239000011669 selenium Substances 0.000 claims 5
- 206010012735 Diarrhoea Diseases 0.000 claims 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- JIMHYXZZCWVCMI-ZSOIEALJSA-N 4-[(z)-[4-oxo-2-sulfanylidene-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1\C=C/1C(=O)N(C=2C=C(C=CC=2)C(F)(F)F)C(=S)S\1 JIMHYXZZCWVCMI-ZSOIEALJSA-N 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 201000009881 secretory diarrhea Diseases 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 238000005462 in vivo assay Methods 0.000 claims 1
- 210000002011 intestinal secretion Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000010171 animal model Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des compositions, des préparations pharmaceutiques et des procédés permettant d'inhiber la protéine CFTR, utiles pour l'étude et le traitement des maladies dont la médiation est assurée par la protéine CFTR. Les compositions et les préparations pharmaceutiques peuvent comprendre un ou plusieurs composés thiazolidinone, et par ailleurs un ou plusieurs vecteurs, excipients et/ou adjuvants pharmaceutiquement acceptables. Les procédés consistent, selon certaines variantes, à administrer au patient soufrant d'une maladie ou d'une affection dont la médiation est assurée par la protéine CFTR une quantité efficace de composé thiazolidinone. Sous d'autres variantes, on décrit des procédés inhibant la protéine CFTR qui consistent à mettre en contact des cellules du patient avec une quantité efficace de composé thiazolidinone. L'invention concerne également un modèle animal non humain de maladie dont la médiation est assurée par la protéine CFTR, résultant de l'administration d'un composé thiazolidinone à un animal non humain, en quantité suffisante pour inhiber la protéine CFTR.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/262,573 | 2002-09-30 | ||
| US10/262,573 US20040063695A1 (en) | 2002-09-30 | 2002-09-30 | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| US48025303P | 2003-06-20 | 2003-06-20 | |
| US60/480,253 | 2003-06-20 | ||
| PCT/US2003/031005 WO2004028480A2 (fr) | 2002-09-30 | 2003-09-30 | Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2500498A1 true CA2500498A1 (fr) | 2004-04-08 |
| CA2500498C CA2500498C (fr) | 2012-08-21 |
Family
ID=32044981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2500498A Expired - Fee Related CA2500498C (fr) | 2002-09-30 | 2003-09-30 | Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1549321A4 (fr) |
| JP (1) | JP4977319B2 (fr) |
| KR (1) | KR20050061501A (fr) |
| CN (1) | CN100356922C (fr) |
| AP (1) | AP2005003292A0 (fr) |
| AU (1) | AU2003277162C1 (fr) |
| BR (1) | BR0314943A (fr) |
| CA (1) | CA2500498C (fr) |
| EA (1) | EA009847B1 (fr) |
| MX (1) | MXPA05003366A (fr) |
| NZ (1) | NZ538809A (fr) |
| PL (1) | PL376147A1 (fr) |
| WO (1) | WO2004028480A2 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8207205B2 (en) | 2008-04-21 | 2012-06-26 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US8283351B2 (en) | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| PL2674428T3 (pl) | 2006-04-07 | 2017-01-31 | Vertex Pharmaceuticals Incorporated | Modulatory transporterów z kasetą wiążącą ATP |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| AU2008302598B2 (en) * | 2007-08-24 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis |
| SI2578571T1 (sl) | 2007-11-16 | 2016-01-29 | Vertex Pharmaceuticals Incorporated | Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto |
| HRP20170241T2 (hr) | 2007-12-07 | 2023-03-17 | Vertex Pharmaceuticals Incorporated | Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline |
| AU2009228307A1 (en) * | 2008-03-25 | 2009-10-01 | The Regents Of The University Of California | Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator |
| DK2615085T3 (en) | 2008-03-31 | 2015-10-05 | Vertex Pharma | Pyridyl derivatives as CFTR modulators |
| US20110237528A1 (en) * | 2008-09-19 | 2011-09-29 | Institute For Oneworld Health | Compositions and methods comprising imidazole and triazole derivatives |
| US20120219543A1 (en) * | 2009-10-20 | 2012-08-30 | Raphael Scharfmann | Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis |
| NZ700556A (en) | 2010-03-25 | 2016-04-29 | Vertex Pharma | Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| DK3150198T3 (da) | 2010-04-07 | 2021-11-01 | Vertex Pharma | Farmaceutiske sammensætninger af 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-yl)-cyclopropancarboxamido)-3-methylpyriodin-2-yl)benzoesyre og indgivelse deraf |
| RS54783B1 (sr) | 2010-04-07 | 2016-10-31 | Vertex Pharma | Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline |
| CA2797118C (fr) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Procede de production de composes de cycloalkylcarboxamido-indole |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| BR112013004443A8 (pt) | 2010-08-23 | 2018-01-02 | Vertex Pharma | composições farmacêuticas de (r)-1-(2,2-difluorbenzo[d] [1,3]dioxol-5-il)-n-(1-(2,3-di-hidróxipropil)-6-flúor-2-(1-hidróxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropano carboxamida e administração das mesmas |
| CN102133402B (zh) * | 2011-03-24 | 2013-06-12 | 首都医科大学附属北京同仁医院 | 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用 |
| WO2012153775A1 (fr) | 2011-05-10 | 2012-11-15 | 国立大学法人神戸大学 | Dérivé de thioxothiazolidine ayant un effet inhibiteur sur la fonction ras |
| MX357328B (es) | 2011-11-08 | 2018-07-05 | Vertex Pharma | Moduladores de trasportadores de casete enlazante de atp. |
| SG10201606135TA (en) | 2012-01-25 | 2016-09-29 | Vertex Pharma | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| EP2872122A1 (fr) | 2012-07-16 | 2015-05-20 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques de (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide et son administration |
| SMT202500078T1 (it) | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| FR2999191B1 (fr) | 2012-12-12 | 2016-02-05 | Lesaffre & Cie | Souches probiotiques pour le traitement et/ou la prevention de la diarrhee |
| RS62140B1 (sr) | 2014-04-15 | 2021-08-31 | Vertex Pharma | Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze |
| IL313498A (en) | 2014-10-06 | 2024-08-01 | Vertex Pharma | Modulators of the cystic fibrosis transmembrane conductance regulator |
| CN104398509B (zh) * | 2014-11-13 | 2017-01-11 | 四川大学华西第二医院 | CFTR抑制剂CFTRinh-172在制备防治白血病细胞介导的疾病的药物中的应用 |
| CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
| AU2016377782B2 (en) * | 2015-12-24 | 2021-07-29 | The Regents Of The University Of California | CFTR regulators and methods of use thereof |
| MX2021013639A (es) | 2016-12-09 | 2022-09-30 | Vertex Pharma | Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística. |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US11465985B2 (en) | 2017-12-08 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| CN114007623A (zh) * | 2019-06-12 | 2022-02-01 | 加利福尼亚大学董事会 | 治疗胆汁酸性腹泻的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96654A (en) * | 1989-12-21 | 1995-06-29 | Lilly Co Eli | Hydroxybenzyl substituted sulfur containing heterocyclic derivatives their preparation and pharmaceutical compositions containing them |
| AU1090795A (en) * | 1993-11-12 | 1995-05-29 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
| US6423708B1 (en) * | 1996-09-30 | 2002-07-23 | Pfizer Inc | Aralkyl and aralkylidene heterocyclic lactams and imides |
| UA56185C2 (uk) * | 1996-09-30 | 2003-05-15 | Пфайзер Інк. | Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування |
| ID27787A (id) * | 1998-08-21 | 2001-04-26 | Viro Pharma Inc | Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan |
| US6484397B1 (en) * | 2000-07-11 | 2002-11-26 | Corning Incorporated | Method of assembling a catalytic converter for use in an internal combustion engine |
| US20020052396A1 (en) * | 2001-04-23 | 2002-05-02 | Bailey Thomas R. | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
-
2003
- 2003-09-30 CA CA2500498A patent/CA2500498C/fr not_active Expired - Fee Related
- 2003-09-30 EA EA200500583A patent/EA009847B1/ru not_active IP Right Cessation
- 2003-09-30 PL PL03376147A patent/PL376147A1/xx not_active Application Discontinuation
- 2003-09-30 WO PCT/US2003/031005 patent/WO2004028480A2/fr not_active Ceased
- 2003-09-30 AU AU2003277162A patent/AU2003277162C1/en not_active Ceased
- 2003-09-30 CN CNB038233665A patent/CN100356922C/zh not_active Expired - Fee Related
- 2003-09-30 KR KR1020057005551A patent/KR20050061501A/ko not_active Abandoned
- 2003-09-30 JP JP2004540305A patent/JP4977319B2/ja not_active Expired - Fee Related
- 2003-09-30 BR BR0314943-9A patent/BR0314943A/pt not_active IP Right Cessation
- 2003-09-30 AP AP2005003292A patent/AP2005003292A0/xx unknown
- 2003-09-30 EP EP03798805A patent/EP1549321A4/fr not_active Withdrawn
- 2003-09-30 NZ NZ538809A patent/NZ538809A/en not_active IP Right Cessation
- 2003-09-30 MX MXPA05003366A patent/MXPA05003366A/es active IP Right Grant
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8283351B2 (en) | 2007-04-02 | 2012-10-09 | Institute For Oneworld Health | Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof |
| US8207205B2 (en) | 2008-04-21 | 2012-06-26 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003277162B2 (en) | 2009-07-16 |
| CN100356922C (zh) | 2007-12-26 |
| PL376147A1 (en) | 2005-12-27 |
| KR20050061501A (ko) | 2005-06-22 |
| EA009847B1 (ru) | 2008-04-28 |
| EP1549321A4 (fr) | 2007-05-23 |
| AU2003277162A1 (en) | 2004-04-19 |
| WO2004028480A3 (fr) | 2004-07-01 |
| JP4977319B2 (ja) | 2012-07-18 |
| BR0314943A (pt) | 2005-08-02 |
| AU2003277162C1 (en) | 2009-12-24 |
| CN1684686A (zh) | 2005-10-19 |
| EA200500583A1 (ru) | 2005-12-29 |
| MXPA05003366A (es) | 2005-10-05 |
| JP2006503853A (ja) | 2006-02-02 |
| EP1549321A2 (fr) | 2005-07-06 |
| AP2005003292A0 (en) | 2005-06-30 |
| WO2004028480A2 (fr) | 2004-04-08 |
| CA2500498C (fr) | 2012-08-21 |
| NZ538809A (en) | 2008-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2500498A1 (fr) | Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations | |
| JP2006503853A5 (fr) | ||
| CA2373653C (fr) | Nouvelle utilisation de composes comme agents antibacteriens | |
| Mourelle et al. | Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase | |
| WO2005094374A3 (fr) | Composes inhibiteurs de cftr contenant des hydrazides et utilisations de ceux-ci | |
| ES2971878T3 (es) | NR o NMN para mejorar la regeneración del hígado | |
| KR20040025915A (ko) | 디펩티딜 펩티다아제 ｉｖ의 저해제를 이용한 2형당뇨병의 치료 | |
| JP2012520343A (ja) | 代謝障害治療のための併用療法 | |
| EA020849B1 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| JP5669729B2 (ja) | 代謝性障害を治療するのに有用なサリチレートコンジュゲート | |
| KR960041168A (ko) | 베타-아드레날린 효능성 작용물질 | |
| CA2533763A1 (fr) | Composes de cyanoamide utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase | |
| CA2685112A1 (fr) | Utilisation d'un compose i pour prevenir ou traiter une formation de biofilm | |
| Di Pasqua et al. | FXR agonists INT‐787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet‐induced ob/ob mouse model of NASH | |
| Brinkman et al. | Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure | |
| RU2004114560A (ru) | Комбинации, включающие ингибиторы сох-2 и аспирин | |
| US8962687B2 (en) | Method of treating liver disorders | |
| Shtrasburg et al. | Inhibition of the second phase of amyloidogenesis in a mouse model by a single-dose colchicine regimen | |
| EP4247361B1 (fr) | Thérapie combinée pour le traitement d'une maladie du foie | |
| CA2522888A1 (fr) | Agents spasmolytiques pour muscles lisses | |
| CA2468811A1 (fr) | Utilisation pharmaceutique d'inhibiteurs d'affections oculaires induites par l'angiogenese | |
| BR0012502A (pt) | Inibidores da expressão do gene para interleucina 5 | |
| RU2010115647A (ru) | Композиция и способ лечения или профилактики доброкачественной гиперплазии предстательной железы и симптомов со стороны нижних отделов мочевыводящих путей | |
| HK40096221B (en) | Combination therapy for the treatment of a liver disease | |
| HK40096221A (en) | Combination therapy for the treatment of a liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140930 |